首页> 外国专利> Tiadiazoles receptor ligands as CXC and CC Chemokine; Pharmaceutical compositions containing as the active ingredient and Use thereof in the preparation of medicines.

Tiadiazoles receptor ligands as CXC and CC Chemokine; Pharmaceutical compositions containing as the active ingredient and Use thereof in the preparation of medicines.

机译:Tiadiazoles受体配体,如CXC和CC趋化因子;含有作为活性成分的药物组合物及其在药物制备中的用途。

摘要

Currently, thiadiazepine is called the adhesive of CXC and CC chemotherapy receivers. These compounds help to treat various diseases caused by chemotherapy, such as cancer, angioplasty, eye vascular disease, lung disease, multiple sclerosis, rheumatoid arthritis, skeletitis and stroke. A formula compound (1a) is used to cause ischemic injury by repulsion, pain (such as acute pain, acute and chronic inflammatory pain, and neuralgia). Claim 1: a compound of formula (1a) and a salt acceptable for the same agent,where: A is selected from the group of formulas (2) where the preceding rings of said groups A are substituted with 1 to 6 substituents, each independently selected from the group consisting of R9 groups (formulas 3) in which or both anterior rings of said groups A are substituted with 1 to 6 substituents each independently selected from the group consisting of R9 groups (formulas 4) where the above phenyl rings of said groups A are substituted with 1 to 3 substituents each independently selected from the group consisting of R9 groups; (formulas 5) and B is selected from the group consisting of (formulas 6),n is 0 to 6; p is 1 to 5; X is O, NR18 or S; Z s 1 to 3; R2 is selected from the group consisting of: H, OH, -C (O) OH, -SH, -SO2NR13R14, -NHC (O) R13, -NHSO2NR13R14, -NHSO2R13, -NR13R14, - C (O) NR13R14, - C (O) NHOR13, -C (O) NR13OH, -S (O2) OH, -OC (O) R13, an unsubstituted heterocyclic acid functional group and a substituted heterocyclic acid functional group; wherein there are 1 to 6 substituents in said substituted heterocyclic acid functional group, where each substituent is independently selected from the group consisting of: R9 groups; each R3 and R4 is independently selected from the group consisting of H, cyano, halogen, alkyl, alkoxy,cycloalkyl substituted with 1 to 4 alkyl groups where each alkyl group is independently selected, unsubstituted cycloalkyl, cycloalkyl substituted with 1 to 4 alkyl groups, -OH, -CF3, -OCF3, -NO2, -C (O) R13, -C (O) OR13, -C (O) NHR17, -C (O) NR13R14, - SO (t) NR13R14, -SO (t) R13, -C (O) NR13OR14, unsubstituted or substituted aryl, unsubstituted heteroaryl or substituted formulas (7),Among them, there are 1-6 substitutes in the replaced arilo, each of which is selected from a separate R9 group consisting of: R9 group, 1-6 substitutes in the replaced heterogeneous group, each of which is selected from a separate group consisting of R9 group; O R3 and R4 combine with C atom and b-phenyl (a compound (formula 6)),They form a combined formula ring (8), in which Z1 or Z2 is a saturated heterocycle that has not been replaced or replaced (preferably a heterocycle of 4 to 7 members),Among them, the Z1 or Z2 ring optionally includes an extra heteromorphic atom selected from the group, which is composed of O, s and N18; there are 1 to 3 substitutes of Z1 or Z2, each of which is located in the,independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, - C (O) OR15, -C (O) NR15R16, -SOtNR15R16 , -C (O) R15, -SO2R15 with the proviso that R15 is not H, -NHC (O) NR15R16, -NHC (O) OR15, halogen and a heterocycloalkenyl group; each R5 and R6 are the same or different and are independently selected from the group consisting of: H, halogen, alkyl, alkoxy, CF3, -OCF3, -NO2, -C (O) R13, -C (O) OR13, -C (O) NR13R14, -SO (t) NR13R14, -C (O) NR13OR14, cyano,a. Arilo that is not replaced or replaced and a heterosexual group that is not replaced or replaced; in these groups, there are 1 to 6 replacement arilo, each of which is selected independently from the following groups: Where there are 1 to 6 alternatives, each of which is selected from a separate group consisting of R9; each R7 and R8 is selected from a separate group consisting of H, unreplaced or substituted bitumen, unreplaced or substituted arilo, Alien not replaced or replaced, alien not replaced or replaced, alien not replaced or replaced,There are no substituted or replaced cycloquinolones, no substituted or replaced cycloquinolones, co2r13, conr13r14, asphalt, alquinio and cycloquinolene; among these substitutes, R7 and R8 of one or more substitutes are selected independently from the following categories: -R13 (E) - nr13r14 (f) - NO2 (g) - CN (H) - so2r13, I) - if (either party) 3, each party is independently selected, (J) - if (arilo) 3, each party is independently selected, (k) (R13) 2r14si, each R13 (L) - co2r13, m) - C (o) nr13r14, n) - so2n13r14, O) - so2r13, P) - OC (o) R13,(q) OC (o) nr13r14, R) - n13c (o) R14, y (s) - n13co2r14 (fluorotar is a non limiting example of a halogenated tar group);R8a is selected from a group consisting of H, asphalt, cyclopentanediol a n d cyclopentanediol; each R9 is independently selected from a group consisting of: (a) R13, (b) halogen, (c) CF3, (d) - cor13, (E) - or13, f) - nr13r14, g) - NO2, H) - C N, I) - so2r13, J) - so2n13r14, K) - n13cor14, l) - conr13r14, m) - nr13r14, n) - cor13, (o) Or R-Nhso2nr13r14, - nhso2r13, - C (o) nr13r14, - C (o) nr13, - OC (o) R13 and cyanogen; R12 is selected from H-C (o) R13, not replaced or replaced by arilo, not replaced or replaced by alien arilalquilo, not replaced or replaced by cyclododecane, replaced or replaced by asphalt In this case, there are 1 to 6 substitutes in R12 group, each of which is selected independently from the following groups: R9 group; each of R13 and R14 group is selected independently from the following groups:Unreplaced or substituted tar, unreplaced or substituted cyanopropyl compounds, unreplaced or substituted arilo, unreplaced or substituted heterosexual, unreplaced or substituted heterosexual 1. Not replaced or replaced Cycas (Cycas) tequila, not replaced or replaced aperiodically, not replaced or replaced fluorojoules, not replaced or replaced aperiodicallyAmong these R13 and R14 alternatives, there are 1 to 5 alternatives, each of which is selected separately from the following categories: pitch-cf3-oh, Alcoy, arilo, arilalquilo, fluorotar, cyclopentanediol, cyclopentadienyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl Halogen, - NHC (o) n15r16 and - so2r15, provided R15 is not h; and, for the substituted cyano methyl ion and the substituted cyano hcyclohexane, the C atom attached to the cyano group is also not connected with the C atom, provided that the alternatives selected from group C include: - Oh, alcox, - n (R40) 2,Halogen y-nhc (o) n15r16; or R13 and R14 are combined with n groups in N group to form a saturated heterocycle which is not replaced or replaced, and the heterocycle can selectively contain an additional heteroatom selected from O.S and nr18 groups; There are 1 to 3 substitutes in the substituted R13 and R14 converters, each of which is independently selected from the following categories: CN, tar, cyanopropyl compound, arilo, hidroxi, oxyhydrogen compound, alcoxi, arilalquilo, fluorotar, cyclopentadienyl, cyandiallyl, cyclopropyl methanol, isopropyl sulfonylpropyl ester, CYCLOPROPYLENE allyl propyl propyl propyl propyl ester, isopropylene allyl propyl ester, Heteromorph, amino, propyl (o) or15,-C (o) n15r16, - sotnr15r16, - C (o) R15, - so2r15 (if R15 is not h),-NHC (O) NR15R16 -NHC (O) OR15 hal geno y un grupo heterocicloalquenilo y con la condici n de que el tomo de C al cual est unido el grupo ciano no tenga que estar tambi n unido al dicho tomo de C un sustituyente Each R19 and R20 is selected from a separate category consisting of asphalt, ash and heterogeneity; R30 is selected from a category consisting of cyclopropene CN -, NO2, or so2r15, provided that R15 should not be h; and each R31 is selected from a separate category consisting of: a. Arilo that is not replaced or replaced, ariarilo that is not replaced or replaced, cyclomequine that is not replaced or replaced;Among these R31 alternatives, there are 1 to 6 alternatives, each of which is selected separately from the following groups:
机译:目前,噻二氮杂被称为CXC和CC化疗接受者的粘合剂。这些化合物有助于治疗由化学疗法引起的各种疾病,例如癌症,血管成形术,眼血管疾病,肺部疾病,多发性硬化症,类风湿性关节炎,骨骼炎和中风。式(1a)化合物用于通过排斥,疼痛(例如急性疼痛,急性和慢性炎性疼痛和神经痛)引起缺血性损伤。权利要求1:式(1a)的化合物和相同试剂可接受的盐,其中:A选自式(2)的组,其中所述组A的前述环分别被1-6个取代基取代选自R 9基团(式3),其中所述基团A的一个或两个前环被1-6个取代基取代,每个取代基独立地选自R 9基团(式4),其中所述苯环的上述苯环基团A被1-3个取代基取代,每个取代基独立地选自R9基团; (式5),B选自(式6),n为0至6; p为1至5; X为O,NR18或S; Z s 1到3; R 2选自:H,OH,-C(O)OH,-SH,-SO2NR13R14,-NHC(O)R13,-NHSO2NR13R14,-NHSO2R13,-NR13R14,-C(O)NR13R14,- C(O)NHOR13,-C(O)NR13OH,-S(O2)OH,-OC(O)R13,未取代的杂环酸官能团和取代的杂环酸官能团;其中在所述取代的杂环酸官能团中有1-6个取代基,其中每个取代基独立地选自:R9基团;每个R 3和R 4独立地选自H,氰基,卤素,烷基,烷氧基,被1-4个烷基取代的环烷基,其中每个烷基独立地选自,未取代的环烷基,被1-4个烷基取代的环烷基, -OH,-CF3,-OCF3,-NO2,-C(O)R13,-C(O)OR13,-C(O)NHR17,-C(O)NR13R14,-SO(t)NR13R14,-SO( t)R13,-C(O)NR13OR14,未取代或取代的芳基,未取代的杂芳基或取代的式(7),其中,在取代的芳基中有1-6个取代基,每个选自以下独立的R9基团: of:R9基团,被取代的异构基团中的1-6个取代基,每个选自由R9基团组成的单独基团; O R3和R4与C原子和b-苯基(一种化合物(式6))结合,形成一个组合式环(8),其中Z1或Z2是未被取代或未取代的饱和杂环(优选a 4至7个成员的杂环),其中,Z 1或Z 2环任选地包含选自由O,s和N 18组成的组的额外的多态原子。 Z 1或Z 2的1-3个取代基,每个取代基均独立地选自:烷基,芳基,羟基,羟烷基,烷氧基,烷氧基烷基,芳基烷基,氟代烷基,环烷基,环烷基烷基,杂芳基,杂芳基烷基,氨基,-C(O)OR15,-C(O)NR15R16,-SOtNR15R16,-C(O)R15,-SO2R15,条件是R15不是H,-NHC(O)NR15R16,-NHC(O) OR15,卤素和杂环烯基;每个R 5和R 6相同或不同,并且独立地选自:H,卤素,烷基,烷氧基,CF 3,-OCF 3,-NO 2,-C(O)R 13,-C(O)OR 13,- C(O)NR13R14,-SO(t)NR13R14,-C(O)NR13OR14,氰基,a。未替换或替换的阿里洛和未替换或替换的异性恋群体;在这些组中,有1至6个取代芳基,每个独立地选自以下组:其中有1至6个替代物,每个均选自由R9组成的单独组;每个R7和R8均选自H,未取代或取代的沥青,未取代或取代的arilo,未取代或未取代的外星人,未取代或未取代的外星人,未取代或未取代的外星人,没有取代或取代的环喹诺酮,co2r13,conr13r14,沥青,alquinio和cycloquinolene;在这些替代物中,一个或多个替代的R7和R8选自以下类别:-R13(E)-nr13r14(f)-NO2(g)-CN(H)-so2r13,I)-如果(任何一方)3,分别选择每一方,(J)-如果(arilo)3,则独立选择每一方,(k)(R13)2r14si,每个R13(L)-co2r13,m)-C(o)nr13r14, n)-so2n13r14,O)-so2r13,P)-OC(o)R13,(q)OC(o)nr13r14,R)-n13c(o)R14,y(s)-n13co2r14(氟代烃是非限制性实例R8a选自由H,沥青,环戊二醇和环戊二醇组成的组;每个R9独立地选自:(a)R13,(b)卤素,(c)CF3,(d)-cor13,(E)-or13,f)-nr13r14,g)-NO2,H) -CN,I)-so2r13,J)-so2n13r14,K)-n13cor14,l)-conr13r14,m)-nr13r14,n)-cor13,(o)或R-Nhso2nr13r14,-nhso2r13,-C(o)nr13r14,-C(o)nr13,-OC(o )R13和氰; R12选自HC(o)R13,不取代或不被arilo取代,不替换或不被外来阿里阿基奎洛取代,不被取代或被环十二烷取代,不被沥青取代或替换在这种情况下,R12组中有1-6个取代,每个独立地选自以下组:R9组; R13和R14基团各自独立地选自下列基团:未取代或取代的焦油,未取代或取代的氰丙基化合物,未取代或取代的芳基,未取代或取代的异性,未取代或取代的异性1.龙舌兰酒在这些R13和R14替代品中,有1-5个替代品,每种替代品均选自以下类别:pitch-cf3-oh,Alcoy, arilo,arilalquilo,fluortar,环戊二醇,环戊二烯基丙烯基丙烯基丙烯基丙烯基丙烯基丙烯基丙烯基丙烯基丙烯基丙烯基丙烯基丙烯基丙烯基R15不是h;并且,对于取代的氰基甲基离子和取代的氰基环己烷,与氰基相连的C原子也未与C原子连接,条件是选自C组的替代物包括:-Oh,醇,-n(R40 )2,卤素y-nhc(o)n15r16;或者R13和R14与N基团中的n个基团结合形成不被取代或取代的饱和杂环,并且该杂环基可以选择性地包含选自OsS和nr18基团的另外的杂原子;取代的R13和R14转换器中有1-3个取代基,每个取代基均独立选自以下类别:CN,焦油,氰基丙基化合物,芳基,羟基,氢氧化合物,醇氧基,芳基铝基,氟代,环戊二烯基,氰基二烯丙基,环丙基甲醇,异丙基磺酰基丙基酯,环丙烯基丙基丙基丙基丙基丙基丙酯,异丙烯基丙基丙基丙基酯,异形物,氨基,丙基(o)或15,-C(o)n15r16,-sotnr15r16,-C(o)R15,-so2r15(if R15不是h),-NHC(O)NR15R16 -NHC(O)OR15 hal geno y un grupo异环戊烯基酮con condicici de que el tomo de C al cual est unido el grupo ciano no tenga que estar tambi n unido al每一个R19和R20选自沥青,灰分和异质性组成的单独类别; R30选自环丙烯CN,NO2或so2r15,条件是R15不应为h;每个R31选自以下单独的类别:未替换或替换的Arilo,未替换或替换的ariarilo,未替换或替换的环mequine;在这些R31替代方案中,有1至6个替代方案,每种选自以下组:

著录项

  • 公开/公告号AR046791A1

    专利类型

  • 公开/公告日2005-12-21

    原文格式PDF

  • 申请/专利号AR2004P104753

  • 发明设计人

    申请日2004-12-17

  • 分类号C07D285/06;C07D417/12;C07D417/14;A61K31/433;A61K31/4402;A61K31/496;A61K31/5375;A61P35/00;A61P25/28;A61P19/00;A61P33/06;A61P31/04;A61P37/06;

  • 国家 AR

  • 入库时间 2022-08-21 21:40:27

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号